TABLE 1

Analysis of covariance results of the wheal and flare endpoints

Time Point after Dosing	Treatment	Subjects^{^a}	LSM	S.E.	Difference of Active Drug versus Placebo
Time Point after Dosing	Treatment	Subjects^{^a}	LSM	S.E.	LSM	S.E.	95% Confidence Interval	t Value	Pr > \|t\|
		n
Wheal area (cm²)
2 h	Placebo	24	1.795	0.1139
	JNJ 39758979	23	1.919	0.1167	0.125	0.1544	−0.187, 0.436	0.81	0.4240
	Cetirizine	24	0.856	0.1139	−0.939	0.1523	−1.246, -0.632	6.16	0.0000
6 h	Placebo	24	1.587	0.0732
	JNJ 39758979	23	1.469	0.0750	−0.119	0.1049	−0.328, 0.091	−1.13	0.2622
	Cetirizine	24	0.434	0.0732	−1.154	0.1036	−1.361, -0.947	−11.14	0.0000
Flare area (cm²)
2 h	Placebo	24	52.191	2.1027
	JNJ 39758979	23	53.127	2.1400	0.936	2.3130	−3.727, 5.600	0.40	0.6876
	Cetirizine	24	36.459	2.1027	−15.732	2.2772	−20.324, -11.140	−6.91	0.0000
6 h	Placebo	24	53.691	2.1642
	JNJ 39758979	23	50.880	2.2054	−2.811	2.4757	−7.808, 2.186	−1.14	0.2626
	Cetirizine	24	23.215	2.1642	−30.475	2.4376	−35.396, -25.555	−12.50	0.0000